Mustang Bio (NASDAQ:MBIO) Shares Down 1.6% – What’s Next?

Posted by Stanley Muller on May 27th, 2026

Mustang Bio, Inc. (NASDAQ:MBIO – Get Free Report) shares were down 1.6% during trading on Tuesday . The company traded as low as $0.61 and last traded at $0.6220. Approximately 32,397 shares were traded during trading, a decline of 22% from the average daily volume of 41,424 shares. The stock had previously closed at $0.6321.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mustang Bio in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Get Our Latest Research Report on Mustang Bio

Mustang Bio Price Performance

The stock has a market cap of $4.71 million, a P/E ratio of -1.30 and a beta of 2.11. The business’s 50 day simple moving average is $0.73 and its 200 day simple moving average is $0.94.

Mustang Bio (NASDAQ:MBIO – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($140.00) by $139.86.

Institutional Trading of Mustang Bio

An institutional investor recently bought a new position in Mustang Bio stock. DRW Securities LLC acquired a new position in shares of Mustang Bio, Inc. (NASDAQ:MBIO – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 73,936 shares of the company’s stock, valued at approximately $73,000. DRW Securities LLC owned approximately 1.01% of Mustang Bio at the end of the most recent quarter. Institutional investors and hedge funds own 9.95% of the company’s stock.

Mustang Bio Company Profile

(Get Free Report)

Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.